We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Maxcyte Inc
11 own
17 watching
Current Price
$4.09
$0.05
(1.24%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
418.81M
52-Week High
7.5
52-Week Low
3.36
Average Volume
0.3M
Dividend Yield
--
P/E Ratio
--
Market Capitalization418.81M52-Week High7.552-Week Low3.36Average Volume0.3MDividend Yield--P/E Ratio--What does the Maxcyte Inc do?
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Read More
How much money does Maxcyte Inc make?
News & Events about Maxcyte Inc.
Globe Newswire
2 months ago
MaxCytes Scientific Advisory Board will provide guidance to shape the technical direction of the companys innovation initiatives focused on the discovery, development and manufacturing of next-generation, cell-based medicinesROCKVILLE, Md., March 08, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: ...
Globe Newswire
5 months ago
Curamys to use MaxCytes Flow Electroporation technology and ExPERT platform to help advance its cell fusion technology.ROCKVILLE, Md. and SEOUL, South Korea, Dec. 04, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling ...
Ticker Report
7 months ago
MaxCyte, Inc. (NASDAQ:MXCT Get Rating) EVP Thomas M. Ross sold 4,282 shares of the businesss stock in a transaction that occurred on Tuesday, October 11th. The stock was sold at an average price of $6.51, for a total transaction of $27,875.82. The transaction was disclosed in a filing...
Ticker Report
9 months ago
MaxCyte (NASDAQ:MXCT Get Rating) had its target price raised by BTIG Research from $10.00 to $11.00 in a report issued on Sunday, The Fly reports. MaxCyte Price Performance Shares of MXCT opened at $5.87 on Friday. The stock has a market capitalization of $596.55 million and a P/E ratio of -...
Globe Newswire
10 months ago
GAITHERSBURG, Md., July 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, ...
Frequently Asked Questions
Frequently Asked Questions
What is Maxcyte Inc share price today?
Can Indians buy Maxcyte Inc shares?
How can I buy Maxcyte Inc shares from India?
Can Fractional shares of Maxcyte Inc be purchased?
What are the documents required to start investing in Maxcyte Inc stocks?
What is today’s traded volume of Maxcyte Inc?
What is today’s market capitalisation of Maxcyte Inc?
What is the 52-Week High and Low Range of Maxcyte Inc?
What percentage is Maxcyte Inc down from its 52-Week High?
What percentage is Maxcyte Inc up from its 52-Week Low?
Current Price
$4.09
$0.05
(1.24%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.